GSE233112 doxorubicin 2 v 3 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE233112_doxorubicin_2_v_3_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE233112_doxorubicin_2_v_3_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE233112_doxorubicin_2_v_3_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE233112_doxorubicin_2_v_3_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

small nucleolar RNA host gene 3

Gene

mir-100-let-7a-2-mir-125b-1 cluster host gene

Gene

HOXA transcript antisense RNA, myeloid-specific 1

Gene

TALAM1 transcript, MALAT1 antisense RNA

Gene

firre intergenic repeating RNA element

Gene

MIR31 host gene

Gene

uncharacterized LOC643977

Gene

CYP1B1 antisense RNA 1

Gene

long intergenic non-protein coding RNA 1089

Gene

small nucleolar RNA host gene 19

  • Gene

    small nucleolar RNA host gene 3


  • Gene

    mir-100-let-7a-2-mir-125b-1 cluster host gene


  • Gene

    HOXA transcript antisense RNA, myeloid-specific 1


  • Gene

    TALAM1 transcript, MALAT1 antisense RNA


  • Gene

    firre intergenic repeating RNA element



  • Gene

    uncharacterized LOC643977


  • Gene

    CYP1B1 antisense RNA 1


  • Gene

    long intergenic non-protein coding RNA 1089


  • Gene

    small nucleolar RNA host gene 19

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.